The short version of provocative testing fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-08. Anything still debated is marked as such rather than presented as settled.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
=== Financing the war === A key element in British success was its ability to mobilise the nation's industrial and financial resources, and apply them to defeating France. Though the UK had a population of approximately 16 million against France's 30 million, the French numerical advantage was offset by British subsidies that paid for many of the Austrian and Russian soldiers, peaking at about 450,000 men in 1813. Under the Anglo–Russian agreement of 1803, Britain paid a subsidy of £1.5 million for every 100,000 Russian soldiers in the field. British national output continued to be strong, and the well-organised business sector channeled products into what the military needed. Britain used its economic power to expand the Royal Navy, doubling the number of frigates, adding 50 per cent more large ships of the line, and increasing the number of sailors from 15,000 to 133,000 in eight years after the war began in 1793. France saw its navy shrink by more than half. The smuggling of finished products into the continent undermined French efforts to weaken the British economy by cutting off markets. Subsidies to Russia and Austria kept them in the war. The British budget in 1814 reached £98 million, including £10 million for the Royal Navy, £40 million for the army, £10 million for the allies, and £38 million as interest on the national debt, which had soared to £679 million, more than double the GDP. This debt was supported by hundreds of thousands of investors and taxpayers, despite the higher taxes on land and a new income tax. The cost of the war amounted to £831 million.
If some of the fish they had previously eaten is available this can also be tested to confirm the diagnosis. Preventive efforts include not eating reef fish, not eating high-risk fish such as barracuda, and not eating fish liver, roe, or fish heads. The toxins have no taste or smell, and cannot be destroyed by conventional cooking. There is no specific treatment for ciguatera fish poisoning once it occurs. Mannitol may be considered, but the evidence supporting its use is not very strong. Gabapentin or amitriptyline may be used to treat some of the symptoms. In 2017, the United States Centers for Disease Control (CDC) estimated that around 50,000 cases occur globally each year. Other estimates suggest up to 500,000 cases per year. The risk of death from poisoning is less than 1 in 1,000 according to the CDC. It is the most frequent seafood poisoning, and up to 5% of patients may develop chronic symptoms, which are treatable using the protocols for Chronic Inflammatory Response Syndrome (CIRS) It occurs most commonly in the Pacific Ocean, Indian Ocean, and the Caribbean Sea between the latitudes of 35°N and 35°S. The risk of the condition appears to be increasing due to coral reef deterioration and increasing trade in seafood. Descriptions of the condition date back to at least 1511. The current name, introduced in 1787, is of Cuban Spanish origin and originally referred to the gastropod Cittarium pica.
Carcinoembryonic antigen (CEA) alpha-fetoprotein beta-human chorionic gonadotropin carbohydrate antigen19-9 creatine-kinase BB isoenzyme tissue polypeptide antigen Beta-2 microglobulin beta-glucoronidase lactate dehydrogenase isoenzyme-5 vascular endothelial growth factor Recently cell-free DNA in cerebrospinal fluid has been evaluated as a means of detecting tumor-specific somatic mutations using next-generation sequencing, offering potential for improved tumor detection.
=== Hematologic involvement === Hematologic abnormalities are prevalent in MCTD. Mild lymphadenopathy affects 25–50% of patients, and it is frequently an early symptom of the disease. This usually subsides over time; however, it may reappear during flares. Between 50% and 75% of people with MCTD will experience anemia, lymphopenia, or leukopenia. Anemia of chronic disease is the most common type of anemia seen in MCTD. Thrombocytopenia can develop in MCTD but is less common than leukopenia or anemia.
Sources: en.wikipedia.org
EosFP is a photoactivatable green to red fluorescent protein. Its green fluorescence (516 nm) switches to red (581 nm) upon UV irradiation of ~390 nm (violet/blue light) due to a photo-induced modification resulting from a break in the peptide backbone near the chromophore. Eos was first discovered as a tetrameric protein in the stony coral Lobophyllia hemprichii. Like other fluorescent proteins, Eos allows for applications such as the tracking of fusion proteins, multicolour labelling and tracking of cell movement. Several variants of Eos have been engineered for use in specific study systems including mEos2, mEos4 and CaMPARI.
== Scientific career before and during World War II == Cremer joined Otto Hahn at Kaiser Wilhelm Institute for Chemistry to study radioactive trace compounds in 1937. She moved labs shortly after to concentrate on isotope separation. In 1938, Cremer received her habilitation from the University of Berlin. In any ordinary case, this qualification would lead to faculty positions; however, the Nazi government of the time had passed the Law on the Legal Position of Female Public Servants. The law banned women from senior positions (e.g. professorship) and required women to quit once married. Many women scientists and scholars were left unemployed or limited in career prospects. After World War II began and male scientists and professors were drafted, Cremer was able to obtain a position as a docent in 1940 at the University of Innsbruck in Austria. However, she was informed that she would leave her job once the war had ended and the men came home. Cremer was pleased with her new position and location because she was able to mountain climb, a hobby of hers.
The prime recovery ship was USS Wasp. The recovery was supported by 10,249 U.S. Department of Defense personnel, 134 aircraft, and 26 ships. Postflight medical examination found the astronauts to be in good health, and no significant physiological changes were found.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.